Effects of Ivabradine on Cardiac Circulation in patients with Angina

Benefits of Ivabradine on Myocardial Perfusion in Chronic Stable Angina Pectoris

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

REBEC

Registry ID

RBR-5fysqrh

Enrollment

Unknown

Registered

2023-11-30

Start date

2019-11-21

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Stable Angina

Interventions

Single-Arm Open Study, Phase IV – Prospective Analysis of 20 consecutive patients (18-70 years) referred to Quanta Diagnosis and Therapy with Chronic Stable Angina pectoris and preserved cardiac funct

D03.633.100.079.801

Eligibility

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with chronic stable angina pectoris; aged between 18 and 70 years; who remain symptomatic despite of using beta blockers (maximum tolerated dose) and HR = 70 bpm; sinus rhythm; LVEF >40%; and any ischemia in baseline myocardial perfusion scintigraphy; performed with a physical stress test; in accordance with previous drug therapy

Exclusion criteria

Exclusion criteria: Unstable angina; Myocardial infarction <6 months; LVEF <40%; HR <70 bpm; presence of left bundle branch block; pacemaker; patients who cannot perform a treadmill stress test (physical limitation); pregnancy, breastfeeding or women in childbearing age who are not taking appropriate contraceptive methods; patients with hypersensibility to ivabradine or any component of the formula, cardiogenic shock, acute myocardial infarction, severe hypotension; and patients with contraindication to perform a myocardial scintigraphy.And also strict precautions (ie contraception) are needed in women of childbearing potential (because ivabradine and scintigraphy)

Design outcomes

Primary

Measure	Time frame
Evaluate the percentage of myocardial ischemia through visual and/or automatic analysis of myocardial perfusion scintigraphy (SPECT) after three months of treatment, compared to baseline	—

Secondary

Measure	Time frame
It is expected to notice an improvement in symptoms (angina attacks, consumption of short-acting nitrates, angina according to the classification of the Canadian Society of Cardiology - CCS) evaluated during the consultation visit after three months, compared to the baseline;It is expected to notice an improvement in the patient's exercise capacity assessed by the exercise tolerance parameters (TTE) performed during the scintigraphy examination after three months of treatment, compared to the same examination performed at baseline	—

Measure

Time frame

It is expected to notice an improvement in symptoms (angina attacks, consumption of short-acting nitrates, angina according to the classification of the Canadian Society of Cardiology - CCS) evaluated during the consultation visit after three months, compared to the baseline;It is expected to notice an improvement in the patient's exercise capacity assessed by the exercise tolerance parameters (TTE) performed during the scintigraphy examination after three months of treatment, compared to the same examination performed at baseline

—

Countries

Brazil

Contacts

Public ContactOlimpio Neto

Quanta Diagnóstico por Imagem

olimpiofranca@yahoo.com.br+55(041)988587602

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 8, 2026